Short Interest in Eupraxia Pharmaceuticals Rises 19.4%

Biotech firm sees increase in shares being shorted amid market volatility

Mar. 16, 2026 at 10:42pm

Got story updates? Submit your updates here. ›

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX), a clinical-stage biotech company, saw a 19.4% increase in short interest on its stock in February, with approximately 5.5% of shares now being shorted. The short-interest ratio currently stands at 5.8 days based on the company's average daily trading volume.

Why it matters

Short interest can be an indicator of investor sentiment and market expectations around a company's performance. The rise in short interest on Eupraxia Pharmaceuticals may reflect broader market volatility and uncertainty around the biotech sector, as well as specific concerns about the company's pipeline and financial outlook.

The details

As of February 27th, Eupraxia Pharmaceuticals had short interest totaling 1,979,996 shares, up from 1,658,534 shares on February 12th. This represents approximately 5.5% of the company's outstanding shares. The increase in short interest comes as Eupraxia's stock has seen significant price fluctuations in recent months, with the share price ranging from a low of $2.68 to a high of $9.32 over the past year.

  • As of February 27th, 2026, Eupraxia Pharmaceuticals had short interest totaling 1,979,996 shares.
  • This represents a 19.4% increase from the February 12th, 2026 total of 1,658,534 shares.

The players

Eupraxia Pharmaceuticals Inc.

A clinical-stage biotechnology company dedicated to developing novel therapies for autoimmune and inflammatory diseases.

Got photos? Submit your photos here. ›

The takeaway

The rise in short interest on Eupraxia Pharmaceuticals highlights the volatility and uncertainty surrounding the biotech sector, as investors take both bullish and bearish positions on the company's future prospects. This could signal a need for the company to provide more clarity on its pipeline and financial outlook to reassure investors.